Influenza Epidemic Articles & Analysis
3 news found
“The preclinical results we have obtained make us confident in the ability of our IMX313P-based influenza vaccine candidate to improve the effectiveness of current seasonal influenza prevention,” said Alexandre Le Vert, Chief Executive Officer of Imaxio. ...
To achieve this, it will develop a candidate vaccine comprising a recombinant, proprietary, and highly immunogenic version of the influenza virus nucleoprotein (NP). The candidate vaccine from the OPTIVAC project will be administered in conjunction with current influenza vaccines with the aim of improving their efficacy, particularly in the elderly. ...
Influenza A(H3) is the predominant virus circulating, and is co-circulating with influenza A(H1)pdm09. ...